Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?

Wendy J Ungar1

  • 1Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada. wendy.ungar@sickkids.ca

Pharmacoeconomics
|May 25, 2011
PubMed

Insights

Deriving health utilities for children is challenging due to age and cognitive limitations. Novel approaches, including child-specific instruments and family-centered perspectives, are needed for accurate cost-utility analysis in pediatric health economics.

Area of Science:

  • Health Economics
  • Pediatric Research
  • Quality of Life Measurement

Background:

  • Standard health economic evaluation methods face challenges in child health.
  • A significant limitation is the lack of child-specific preference-based utility measures.
  • Existing measures like EQ-5D and Health Utilities Index are difficult for children to use.

Purpose of the Study:

  • To present and discuss options for deriving utilities for pediatric health states in cost-utility analysis (CUA).
  • To explore novel approaches addressing limitations in child health state valuation.
  • To highlight the importance of methodological rigor in child health economic evaluations.

Main Methods:

  • Review of existing and novel methods for deriving child health utilities.
  • Discussion of direct elicitation challenges (cognitive/age limitations).
  • Exploration of indirect instruments (e.g., EQ-5D-Y, Child Health Utility-9D), proxy reporting, and family-centered valuation approaches.

Main Results:

  • No single, valid, preference-based utility measure exists for all children.
  • Novel instruments (EQ-5D-Y, Child Health Utility-9D) and age-appropriate methods are being developed.
  • Proxy reporting for young children (<6 years) has limitations, especially for subjective outcomes.
  • Family-centered valuation (collective or unitary approaches) offers a promising alternative perspective.
  • Challenges in measurement and validity persist across various methods.

Conclusions:

  • Deriving accurate health utilities for children remains a significant challenge in health economics.
  • Innovative methods, including child-specific tools and family perspectives, are crucial for improving CUA in pediatrics.
  • Further research and rigorous methodology are essential to enhance the value of child health economic evidence for decision-making.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...